Neoplasia — MCQs

Neoplasia Indian Medical PG Practice Questions and MCQs

Question 371: Which of the following can cause transitional cell carcinomas?

A. Naphthylamine
B. Smoking
C. Bilharziasis
D. All of the above (Correct Answer)

Explanation: Transitional Cell Carcinoma (TCC), also known as Urothelial Carcinoma, is the most common malignancy of the urinary bladder. Its development is strongly linked to chronic exposure to environmental and chemical carcinogens. * **Naphthylamine (Option A):** This is a classic industrial carcinogen [1]. Workers in the **dye, rubber, and leather industries** are at high risk [1], [2]. 2-Naphthylamine is metabolized in the liver and excreted in the urine, where it acts as a potent local carcinogen on the urothelium. * **Smoking (Option B):** Cigarette smoking is the **most significant risk factor** for TCC, increasing the risk 3 to 7-fold [2]. Carcinogens like polycyclic aromatic hydrocarbons and nitrosamines are absorbed from the lungs and excreted in the urine [1]. * **Bilharziasis (Option C):** Infection with *Schistosoma haematobium* (Bilharziasis) is a major risk factor [2]. While it is most classically associated with **Squamous Cell Carcinoma (SCC)** due to chronic irritation and squamous metaplasia, it is also a documented risk factor for Transitional Cell Carcinoma in endemic areas. Since all three factors are established etiologies for bladder malignancies, **Option D (All of the above)** is the correct answer. **High-Yield Clinical Pearls for NEET-PG:** 1. **Most common presentation:** Painless gross hematuria. 2. **Field Cancerization:** The entire urothelium (from renal pelvis to urethra) is at risk due to "field effect," meaning tumors are often multifocal and recurrent. 3. **Drugs:** Long-term use of **Cyclophosphamide** (metabolite Acrolein) and **Phenacetin** abuse are also high-yield risk factors for TCC [1]. 4. **Schistosomiasis Distinction:** If a question asks for the *most specific* cancer associated with *S. haematobium*, choose **Squamous Cell Carcinoma**. If it asks what *can* cause TCC, Schistosomiasis remains a valid factor [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 217-218. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 968-970.

Question 372: Microscopic examination of a specimen shows 'Psammoma bodies'. What is the most characteristic association of Psammoma bodies?

A. Follicular carcinoma of the thyroid
B. Papillary carcinoma of the thyroid (Correct Answer)
C. Serous cystadenocarcinoma of the ovary
D. Meningioma

Explanation: **Explanation:** **Psammoma bodies** are concentric, laminated calcified structures representing a form of **dystrophic calcification** [2]. They are formed when single necrotic cells serve as a nidus for the deposition of calcium salts. **Why Option B is Correct:** While Psammoma bodies are seen in several tumors, they are most characteristically associated with **Papillary Carcinoma of the Thyroid (PCT)** [1]. In PCT, they are found in the cores of the papillae. Their presence in a fine-needle aspiration (FNA) or biopsy of a thyroid nodule is highly suggestive of this diagnosis [1]. **Analysis of Other Options:** * **Option A (Follicular Carcinoma):** This tumor is characterized by follicles and vascular invasion; it typically does **not** show Psammoma bodies [3]. * **Option C & D (Serous Cystadenocarcinoma & Meningioma):** Both these tumors frequently exhibit Psammoma bodies. However, the question asks for the "most characteristic" association in a classic pathology context. In medical exams, if Papillary Thyroid Carcinoma is listed alongside these, it remains the primary association. **NEET-PG High-Yield Pearls:** To remember the common tumors associated with Psammoma bodies, use the mnemonic **"PSaMMoma"**: * **P** - **P**apillary carcinoma of thyroid * **S** - **S**erous cystadenocarcinoma of ovary * **M** - **M**eningioma * **M** - **M**esothelioma **Key Fact:** Psammoma bodies are a classic example of **dystrophic calcification** (occurs in necrotic tissues with normal serum calcium levels), as opposed to metastatic calcification (occurs in normal tissues with high serum calcium) [2]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, p. 1099. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 134-135. [3] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Endocrine System, pp. 1096-1097.

Question 373: CD34 is a tumor marker used for which of the following?

A. Ewing sarcoma
B. Myofibrosarcoma
C. Alveolar soft part sarcoma (Correct Answer)
D. Inflammatory myofibroblastic tumor

Explanation: **Explanation:** **CD34** is a transmembrane glycoprotein primarily expressed in hematopoietic stem cells and vascular endothelium [1]. In the context of soft tissue tumors, it is a highly sensitive marker for tumors with vascular differentiation or specific fibroblastic/mesenchymal origins [1]. **Why Alveolar Soft Part Sarcoma (ASPS) is correct:** While ASPS is classically characterized by the **TFE3** expression (due to the $t(X;17)$ translocation), it is highly vascularized with a prominent capillary network surrounding the nests of tumor cells (organoid pattern). CD34 is frequently used to highlight this characteristic **intratumoral vascularity**, which is a diagnostic hallmark of ASPS. **Analysis of Incorrect Options:** * **Ewing Sarcoma:** The gold standard marker is **CD99** (MIC2), showing a diffuse membranous staining pattern. It is typically negative for CD34. * **Myofibrosarcoma:** These tumors typically express **SMA** (Smooth Muscle Actin) and Desmin. CD34 is generally negative, helping to distinguish it from Solitary Fibrous Tumors (SFT). * **Inflammatory Myofibroblastic Tumor (IMT):** The characteristic marker is **ALK** (Anaplastic Lymphoma Kinase) rearrangement/expression (seen in ~50% of cases). **High-Yield Clinical Pearls for NEET-PG:** * **CD34 Positive Tumors (The "S" List):** **S**olitary Fibrous Tumor (Strong/Diffuse), **S**pindle cell lipoma, **S**ermatofibrosarcoma Protuberans (DFSP), and **S**angiosarcoma (Vascular tumors) [1]. * **ASPS Key Fact:** Look for "PAS-positive, diastase-resistant rhomboid crystals" in the cytoplasm. * **GIST:** CD34 is positive in ~70% of Gastrointestinal Stromal Tumors (though **DOG1** and **CD117** are more specific). **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 523-528.

Question 374: Which of the following is not typically seen in the first decade of life?

A. Retinoblastoma
B. Rhabdomyosarcoma
C. Neuroblastoma
D. Ameloblastoma (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Ameloblastoma**. The core medical concept here is the **age-specific incidence of pediatric versus odontogenic tumors**. While many "blastomas" are embryonal tumors occurring in early childhood [1], Ameloblastoma is an odontogenic neoplasm that typically presents in the **3rd to 5th decades of life** (average age 30–40 years). It is extremely rare in the first decade of life. **Analysis of Options:** * **A. Retinoblastoma:** This is the most common intraocular tumor of childhood [3]. Approximately 90% of cases are diagnosed before age 5 [1]. It is often associated with the *RB1* gene mutation on chromosome 13q14 [3]. * **B. Rhabdomyosarcoma:** Specifically the **Embryonal subtype**, this is the most common soft tissue sarcoma in children [2]. It shows a peak incidence in the first decade (2–6 years of age) [2]. * **C. Neuroblastoma:** This is the most common extracranial solid tumor of childhood [2]. About 90% of cases are diagnosed before age 5 [1], frequently presenting as an abdominal mass arising from the adrenal medulla [2]. **NEET-PG High-Yield Pearls:** * **Small Round Blue Cell Tumors:** Retinoblastoma, Neuroblastoma, Wilms tumor, and Ewing sarcoma are classic "small round blue cell tumors" of childhood [2]. * **Ameloblastoma:** It is a "benign but locally invasive" tumor. The most common site is the **mandible (molar-ramus area)**. Radiologically, it presents as a **"soap-bubble" appearance**. * **Rule of Thumb:** Most tumors ending in "-blastoma" are pediatric (embryonal), with **Ameloblastoma and Glioblastoma Multiforme (GBM)** being notable exceptions that occur primarily in adults [1]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 211-212. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Diseases of Infancy and Childhood, pp. 483-484. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Manifestations Of Central And Peripheral Nervous System Disease, pp. 737-738.

Question 375: The Ki 67 antigen is a marker associated with which carcinoma?

A. Breast (Correct Answer)
B. Stomach
C. Lung
D. None of the above

Explanation: **Explanation:** **Ki-67** is a non-histone nuclear protein that serves as a potent **proliferation marker**. It is expressed during all active phases of the cell cycle (G1, S, G2, and mitosis) but is notably absent in the resting phase (G0). 1. **Why Breast Carcinoma is Correct:** In clinical practice, Ki-67 is most significantly utilized in the management of **Breast Carcinoma** [1]. It is a key component of the **molecular subtyping** of breast cancer (specifically distinguishing between Luminal A and Luminal B types). A high Ki-67 index (>20%) indicates a highly proliferative tumor, which correlates with a poorer prognosis but often a better response to chemotherapy. It is an essential IHC (Immunohistochemistry) marker used alongside ER, PR, and HER2/neu. 2. **Why Other Options are Incorrect:** * **Stomach and Lung Carcinomas:** While Ki-67 can be expressed in any rapidly dividing cancer cell (including gastric and lung cancers), it is not used as a standard diagnostic or prognostic "signature" marker for these organs in the same way it is standardized for breast cancer. For Lung cancer, markers like TTF-1 or p40 are more specific; for Stomach, HER2 or mismatch repair (MMR) proteins are more clinically relevant. **High-Yield Clinical Pearls for NEET-PG:** * **MIB-1:** This is the most commonly used monoclonal antibody to detect the Ki-67 antigen in paraffin-embedded sections. * **Prognostic vs. Predictive:** Ki-67 is a strong **prognostic** marker (predicts the natural course of the disease). * **Neuroendocrine Tumors (NETs):** Apart from breast cancer, Ki-67 is also the gold standard for **grading** Neuroendocrine tumors (e.g., Carcinoid tumors), where the "Ki-67 index" determines if a tumor is Grade 1, 2, or 3. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1059-1066.

Question 376: Which of the following is NOT a feature of a benign tumor?

A. Absence of hyperchromasia of nucleus
B. Retained basal polarity
C. Slow growth
D. Presence of local invasion (Correct Answer)

Explanation: **Explanation:** The hallmark of malignancy is the ability to breach natural tissue barriers. **Local invasion** is the most reliable feature that distinguishes a malignant tumor from a benign one [2]. Benign tumors typically grow as cohesive, expansile masses that remain localized to their site of origin. They often develop a rim of condensed connective tissue called a **fibrous capsule**, which keeps the tumor well-demarcated and prevents infiltration into adjacent structures [1]. **Analysis of Options:** * **A. Absence of hyperchromasia:** Hyperchromasia (darkly stained nuclei due to increased DNA content) is a feature of **anaplasia** [3]. Benign tumors are well-differentiated and resemble their tissue of origin; therefore, they lack significant nuclear pleomorphism or hyperchromasia [1]. * **B. Retained basal polarity:** In benign epithelial tumors, the orientation of cells relative to the basement membrane (polarity) is preserved. Loss of polarity is a characteristic of dysplasia and malignancy. * **C. Slow growth:** Most benign tumors have a low mitotic index and progress slowly over years, whereas malignant tumors generally exhibit rapid, erratic growth [2]. * **D. Presence of local invasion (Correct):** This is a definitive sign of malignancy. If a tumor infiltrates, invades, or destroys surrounding tissue, it cannot be classified as benign [2]. **NEET-PG High-Yield Pearls:** * **Exceptions to the Rule:** Some benign tumors are *not* encapsulated (e.g., Leiomyoma of the uterus, Hemangioma) [1]. * **The "Gold Standard":** Metastasis is the most definitive criterion for malignancy, but local invasion is the second most reliable [1]. * **Important Exception:** **Gliomas** (CNS tumors) and **Basal Cell Carcinomas** are highly invasive but rarely metastasize [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 276-278. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 206-207. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 204-206.

Question 377: Which of the following is an example of a tumor suppressor gene?

A. myc
B. fos
C. ras
D. RB (Correct Answer)

Explanation: **Explanation:** The correct answer is **RB (Retinoblastoma gene)**. **1. Why RB is the Correct Answer:** The **RB gene**, located on chromosome **13q14** [1], is the "governor of the cell cycle" and the first tumor suppressor gene discovered [1]. It acts as a negative regulator of the cell cycle at the **G1/S checkpoint** [1]. In its hypophosphorylated (active) state, the RB protein binds to the **E2F transcription factor**, preventing the cell from entering the S-phase [1]. When mutated or inactivated, E2F is released, leading to uncontrolled cell proliferation [1]. It follows the "Knudson’s two-hit hypothesis" [1]. **2. Why Other Options are Incorrect:** * **A (myc):** This is a **proto-oncogene** that encodes a nuclear transcription factor [1]. It is associated with Burkitt Lymphoma (c-myc) and Neuroblastoma (n-myc). * **B (fos):** This is a **proto-oncogene** that belongs to the AP-1 transcription factor family, involved in cell proliferation and differentiation. * **C (ras):** This is the most common **proto-oncogene** mutated in human cancers [1]. It encodes a GTP-binding protein involved in signal transduction (MAP kinase pathway). **3. High-Yield Clinical Pearls for NEET-PG:** * **TP53:** Known as the "Guardian of the Genome," it is the most commonly mutated gene in human cancers [1]. * **Two-Hit Hypothesis:** Applies to tumor suppressor genes (like RB and APC), where both alleles must be inactivated for oncogenesis [1]. * **Associated Conditions:** RB mutations are linked to familial Retinoblastoma and an increased risk of **Osteosarcoma** later in life. * **Quiescence vs. Senescence:** RB-mediated arrest can lead to temporary (quiescence) or permanent (senescence) cell cycle exit. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Neoplasia, pp. 297-302.

Question 378: Gleason score is used to grade which malignancy?

A. Prostate cancer (Correct Answer)
B. Transitional cell carcinoma
C. Penile cancer
D. Anal cancer

Explanation: The **Gleason score** is the standard architectural grading system used for **Prostate Adenocarcinoma** [1]. Unlike many other cancers that rely on cellular atypia, the Gleason system is based solely on the **architectural patterns** of the tumor glands under low-power magnification [1]. ### Why Prostate Cancer is Correct: The Gleason score is calculated by identifying the most common (primary) and second most common (secondary) growth patterns, each assigned a grade from 1 to 5 [1]. * **Grade 1:** Small, uniform, well-circumscribed glands. * **Grade 5:** Lack of gland formation, showing solid sheets, cords, or single infiltrating cells. * **Calculation:** The two grades are added (e.g., 3+4=7). A higher score indicates a more aggressive tumor and a poorer prognosis [1]. ### Why Other Options are Incorrect: * **Transitional cell carcinoma (Urothelial cancer):** Graded using the **WHO/ISUP classification**, which categorizes tumors into Low-grade or High-grade based on nuclear features and architectural complexity. * **Penile cancer:** Usually Squamous Cell Carcinoma (SCC), graded using the **Broders’ system**, which assesses the degree of cellular differentiation and keratinization. * **Anal cancer:** Also typically SCC; grading is based on the degree of differentiation (Well, Moderately, or Poorly differentiated) rather than a specific named scoring system like Gleason. ### High-Yield Pearls for NEET-PG: * **ISUP Grade Groups:** Modern pathology now groups Gleason scores into 5 Grade Groups (Group 1 = Score ≤6; Group 5 = Score 9-10) to better predict clinical outcomes. * **Prostate Biopsy vs. Prostatectomy:** On a biopsy, if only one pattern is seen, it is doubled (e.g., 3+3=6). If three patterns are seen, the primary and the *worst* (highest) patterns are added. * **Most common site:** Prostate cancer typically arises in the **peripheral zone** [1]. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lower Urinary Tract and Male Genital System, pp. 989-994.

Question 379: Carcinoid tumors develop from which type of cells?

A. Hematopoietic cells
B. Kulchitsky cells (Correct Answer)
C. Neuroglial cells
D. Chromaffin cells

Explanation: **Explanation:** **Carcinoid tumors** are well-differentiated neuroendocrine neoplasms that arise from the **Kulchitsky cells** (also known as Enterochromaffin cells) [1]. These cells are part of the Diffuse Neuroendocrine System (DNES) and are primarily located in the mucosal lining of the gastrointestinal tract and the bronchial tree [1]. * **Why Option B is correct:** Kulchitsky cells are specialized cells that possess the ability to uptake and de-carboxylate amine precursors (APUD system). They secrete bioactive amines like **serotonin (5-HT)**, histamine, and bradykinin [2]. When these tumors metastasize (usually to the liver), these substances bypass hepatic metabolism, leading to "Carcinoid Syndrome." **Analysis of Incorrect Options:** * **A. Hematopoietic cells:** These are stem cells located in the bone marrow that give rise to blood cells (RBCs, WBCs, Platelets). They are associated with leukemias and lymphomas, not neuroendocrine tumors. * **C. Neuroglial cells:** These are supporting cells of the CNS (astrocytes, oligodendrocytes). Tumors arising from these are called Gliomas. * **D. Chromaffin cells:** While also neuroendocrine, these are specifically located in the **adrenal medulla** [3]. Tumors arising from chromaffin cells are called **Pheochromocytomas** [3]. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Historically the appendix, but recent data suggests the **small intestine (ileum)** is the most common site for symptomatic carcinoids [1]. * **Diagnosis:** 24-hour urinary **5-HIAA** (metabolite of serotonin) is the screening test of choice. * **Histology:** Classic "salt and pepper" chromatin with cells arranged in islands, nests, or trabeculae [2]. * **Markers:** Positive for **Chromogranin A** and **Synaptophysin**. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Gastrointestinal Tract, pp. 780-781. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Lung, p. 727. [3] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Liver And Biliary System Disease, pp. 419-420.

Question 380: Breslow thickness is used in the staging of which of the following conditions?

A. Melanoma (Correct Answer)
B. Squamous cell carcinoma
C. Basal cell carcinoma
D. Actinic keratosis

Explanation: **Explanation:** **Breslow thickness** is the most important prognostic factor and the primary parameter used in the **TNM staging of Malignant Melanoma** [1]. It measures the total vertical height of the tumor in millimeters, from the top of the granular layer (or the base of an ulcer) to the deepest point of tumor involvement in the dermis or subcutaneous tissue [2]. * **Why Melanoma is correct:** Unlike other skin cancers, the risk of metastasis in melanoma correlates directly with the vertical depth of invasion [2]. A higher Breslow thickness indicates a higher likelihood of lymph node involvement and a poorer prognosis [1]. * **Why other options are incorrect:** * **Squamous Cell Carcinoma (SCC) & Basal Cell Carcinoma (BCC):** While depth of invasion is noted, they are not staged using Breslow thickness. SCC staging focuses more on diameter (>2cm), anatomical site, and perineural invasion. BCC rarely metastasizes, making vertical thickness less clinically significant for staging. * **Actinic Keratosis:** This is a precancerous lesion (carcinoma in situ) confined to the epidermis; therefore, measurement of dermal invasion thickness is not applicable. **High-Yield Clinical Pearls for NEET-PG:** 1. **Breslow vs. Clark Level:** Breslow thickness (quantitative/mm) has replaced Clark Level (qualitative/anatomical layer) as the primary staging tool because it is a more accurate predictor of survival. 2. **Sentinel Lymph Node Biopsy (SLNB):** Generally indicated in melanomas with a Breslow thickness **≥ 0.8 mm** or those with ulceration [1]. 3. **Most Common Site:** In males, it is the back; in females, it is the lower legs. 4. **ABCDE Criteria:** Used for clinical screening (Asymmetry, Border irregularity, Color variegation, Diameter >6mm, Evolving). **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Disorders Involving Inflammatory And Haemopoietic Cells, pp. 650-651. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Skin, pp. 1151-1153.

Practice by Chapter

Nomenclature and Classification of Tumors

Practice Questions

Characteristics of Benign and Malignant Neoplasms

Practice Questions

Molecular Basis of Cancer

Practice Questions

Carcinogenesis and Carcinogens

Practice Questions

Tumor Progression and Metastasis

Practice Questions

Tumor Markers

Practice Questions

Paraneoplastic Syndromes

Practice Questions

Genetic Basis of Cancer

Practice Questions

Tumor Immunity

Practice Questions

Cancer Epidemiology and Prevention

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Neoplasia — MCQs

Neoplasia — MCQs

On this page

Practice by Chapter

Want unlimited practice?